Company Research Report: Gustave Roussy
Company Overview
- Name: Gustave Roussy
- Mission: To revolutionize the treatment and understanding of cancer, bringing hope and effective care to patients worldwide.
- Founded: Established in 1921 by Professor Gustave Roussy.
- Key People:
- Prof. Fabrice Barlesi, Director General since August 1, 2021.
- Previous notable directors include Prof. Alexander Eggermont and Prof. Thomas Tursz.
- Headquarters: 114, rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
- Number of Employees: 4,000 professionals are mobilized.
- Revenue: No information is available.
- Known For: Being the number one cancer treatment center in Europe and recognized globally for groundbreaking oncological innovations.
Products
Offered Services
- Research and Treatments: Specializes in complex tumors, rare cancers, personalized medicine, and immunotherapy.
- Technological Infrastructure: Includes robotic surgery, state-of-the-art radiotherapy, and genomics.
Key Features
- Integrated Research: Combines clinical, translational, and fundamental research for swift advancements in cancer therapy.
- Smart Hospital Initiative: Focuses on ultra-personalized care pathways and rapid, impactful research collaborations.
Recent Developments
Innovations
- Metro Station Opening: In January 2025, the metro station Villejuif–Gustave Roussy was inaugurated, enhancing accessibility to the institute.
- Awards: Introduced the Gustave Roussy Prize, recognizing significant contributions to cancer research.
Campaigns
- Television Campaign: In January 2025, launched a campaign to raise donations for continued cancer research.
- Promotional Awareness: Highlighted leading treatments and research capabilities through media engagements.
Partnerships
- European Excellence: Participates in Cancer Core Europe, consolidating collaborative efforts with other major European oncology centers.
- Corporate Sponsorships: Collaborations with entities like Pierre Fabre Laboratories for initiatives like the Gustave Roussy Prize.
This report offers a consolidated view based solely on the data provided without extraneous or speculative commentary, ensuring a purely factual representation of Gustave Roussy's current standing and future outlook in the domain of oncological healthcare and research.
